The deal, the financial terms of which were not disclosed, allows Philips to distribute the CorPath 200 system in the U.S.
Corindus calls the CorPath 200 "the world’s 1st robotic-assisted system for the minimally invasive treatment of obstructed coronary arteries in patients with Coronary Artery Disease."
The device, which won FDA clearance in July for performing percutaneous coronary interventions, is operated from behind a radiation-shielded "cockpit" where the surgeon can operate while seated.
"Robotic-assisted interventional technologies have great potential to further improve current image-guided minimally invasive procedures, which is a fast growing market with for example more than one million PCI procedures estimated to be performed in the United States in 2012," Philips imaging systems business CEO Gene Saragnese said in prepared remarks. "By teaming up with partners with complementary and unique strengths, such as Corindus Vascular Robotics, we aim to shape the future of healthcare by delivering innovative solutions that enhance clinical capabilities, improve patient outcomes and reduce healthcare costs."
The companies have had a relationship prior to this deal. Philips owns a minority share in Corindus, according to a press release.